Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular ...

On Protocol Rescue-Free Rates As a pre-specified exploratory endpoint, Ocular evaluated the proportion of patients who did ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49 th Macula Society ...

Izervay injections for geographic atrophy led to acute IOP increases in 3% of eyes in a real-world dataset published in ...